folder

The heart in Anderson Fabry disease

Authors

  • C. Kampmann
  • C.M. Wiethoff
  • A. Perrot
  • M. Beck
  • R. Dietz
  • K.J. Osterziel

Journal

  • Zeitschrift fuer Kardiologie

Citation

  • Z Kardiol 91 (10): 786-795

Abstract

  • Anderson Fabry disease is a life threatening, X-linked inborn metabolic defect of the lysosomal enzyme á{alpha}-galactosidase A. The deficiency of {alpha}-galactosidase A leads to a progressive accumulation of globotriaosylceramide (Gb(3)), the major glycosphingolipid substrate of the enzyme, within vulnerable cells, tissues, and organs, including the cardiovascular system. Cardiac involvement is frequent and patients with cardiac affection develop progressive hypertrophic infiltrative cardiomyopathy, valvular abnormalities, arrhythmias, and conduction abnormalities and may develop coronary heart disease. Hemizygous male patients have no detectable {alpha}-galactosidase A activity, while affected heterozygous females may have normal level of {alpha}-galactosidase A activity. Death occurs in male patients at 45 to 50 years, about 15 to 20 years earlier than in female patients due to a vicious circle from chronic renal insufficiency, arterial hypertension, atherosclerotic lesions and cerebrovascular hemorrhage or insults, and cardiomyopathy.    Cardiac involvement in hetero- and hemizygotes will be discussed as well as the influence of enzyme replacement of {alpha}-galactosidase A.


DOI

doi:10.1007/s00392-002-0848-5